טוען...
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
The monoclonal antibody trastuzumab (Herceptin®), which targets the human epidermal growth factor receptor 2 (HER2), is approved for the treatment of early breast and advanced breast and gastric cancer in which HER2 is overexpressed. Several biosimilar versions of trastuzumab are expected to enter t...
שמור ב:
| הוצא לאור ב: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group UK
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6738325/ https://ncbi.nlm.nih.gov/pubmed/31257362 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0480-z |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|